Pharma Mar SA (ES:PHM) has released an update.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Pharma Mar SA’s partner, Luye Pharma Group, has secured conditional approval from China’s National Medical Products Administration for the commercialization of Zepzelca (lurbinectedin) to treat metastatic small cell lung cancer. This marks the drug’s approval in 17 global territories, reflecting its growing acceptance and potential market reach in the oncology sector. The approval is based on promising clinical study results, underscoring the drug’s efficacy and safety for patients in China.
For further insights into ES:PHM stock, check out TipRanks’ Stock Analysis page.